NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAII)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three and six months ended December 31, 2024 (Fiscal Year 2025, Q1 and Q2).

Business Overview: NAII operates in two primary segments: private-label contract manufacturing of nutritional supplements and patent/trademark licensing (primarily beta-alanine ingredients under the CarnoSyn® and TriBsyn™ brands). The company is a smaller reporting company and non-accelerated filer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 35% year-over-year for the quarter and 14% for the six-month period. Private-label contract manufacturing sales drove this growth (up 40% QoQ, 14% YoY), while patent licensing revenue declined 18% in the quarter but grew 9% for the six-month period.
• Profitability: Despite revenue growth, the company reported a net loss. The operating loss widened by 14% for the six-month period compared to the prior year, primarily due to increased manufacturing costs (labor, rent, freight), unfavorable sales mix, and higher SG&A expenses.
• Cash Flow: Operating cash flow turned negative, using $3.4 million in the first six months of FY2025, compared to providing $4.8 million in the same period of FY2024. This shift was driven by changes in working capital, specifically a decrease in inventory levels providing cash in the prior year versus the current year, and increased payments on accounts payable.
• Debt Utilization: Borrowings on the line of credit increased from $3.4 million to $5.0 million to fund operations.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management anticipates an overall net loss for fiscal year 2025, including the second half, despite an expected increase in annualized sales compared to fiscal 2024.
• Credit Facility Covenant Compliance: As of December 31, 2024, the company was not in compliance with financial covenants related to net income requirements and the fixed charge coverage ratio under its Fourth Amendment credit facility. Management expects non-compliance to continue in the next two quarters. The company is negotiating a waiver or revised facility with Wells Fargo, which has agreed not to exercise default options while negotiations are ongoing.
• IRS Dispute: The IRS issued a denial letter regarding a $3.5 million Employee Retention Tax Credit (ERTC) claim for Q3 2021. The company disputes this and has not recorded an allowance against the accrual, though the outcome remains uncertain.
• Geopolitical and Trade Risks: The company faces risks from geopolitical conflicts (Ukraine, Middle East) affecting supply chains and new U.S. tariffs on imports from China, Mexico, and Canada, which could impact the cost and availability of beta-alanine raw materials.
• Customer Concentration: Revenue remains concentrated, with the largest customer accounting for 34% of net sales in the first six months of FY2025 (down from 41% in the prior year).

Key Facts for Investor Verification

• Covenant Status: Verify the outcome of negotiations with Wells Fargo regarding the credit facility covenant waivers, as failure to secure a waiver could trigger a default.
• ERTC Claim: Monitor the status of the IRS dispute regarding the $3.5 million tax credit refund, as a final denial would impact future cash flows and tax benefits.
• Margin Pressure: Assess the sustainability of gross margins given the reported increases in labor, rent, and freight costs, and the shift in sales mix toward lower-margin contract manufacturing.
• Liquidity Runway: Confirm that the current cash balance ($8.7 million) and available credit line ($10.8 million) are sufficient to fund operations through the anticipated net loss period in FY2025.
• Product Launch: Evaluate the market acceptance of the new TriBsyn™ product, which is central to the company's strategy for diversifying revenue beyond traditional beta-alanine sales.